President and Chief Executive Officer of Danaher since May 2001; director of GlaxoSmithKline plc. As the CEO and President of Danaher Corporation led the highly successful transformation of the company from an industrial manufacturer into a leading science and technology company. This transformation was made possible through a disciplined capital allocation approach, including a series of strategic acquisitions and dispositions under Culp’s leadership. Culp drove the evolution of the Danaher Business System, a common operating philosophy and set of tools deployed across Danaher’s portfolio of businesses that enabled superior operating performance and value creation; during his 14 years at the head of Danaher, the company’s market capitalization and revenues grew five-fold. Since retiring from Danaher in 2014, Culp has been a Senior Lecturer at Harvard Business School, where he earned an MBA. He also serves as a Senior Advisor to Bain Capital Private Equity. Culp is a member of the T. Rowe Price Group Board of Directors, chairs the Board of Visitors and Governors of Washington College and is a member of the Wake Forest University Board of Trustees.